Background Blood-biomarkers of Alzheimer’s disease (AD) pathology have been investigated cross-sectionally in heterogenous AD cohorts and shown to detect underlying pathology, even at preclinical stages. However, longitudinal studies, including serial blood-biomarker measurements, are needed better understand whether these markers could help monitor progression. We aimed assess blood-biomarkers...
